Emma Rubenstein

1.1k total citations · 1 hit paper
11 papers, 186 citations indexed

About

Emma Rubenstein is a scholar working on Rheumatology, Infectious Diseases and Molecular Biology. According to data from OpenAlex, Emma Rubenstein has authored 11 papers receiving a total of 186 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Rheumatology, 3 papers in Infectious Diseases and 3 papers in Molecular Biology. Recurrent topics in Emma Rubenstein's work include Vasculitis and related conditions (3 papers), Rheumatoid Arthritis Research and Therapies (3 papers) and IgG4-Related and Inflammatory Diseases (2 papers). Emma Rubenstein is often cited by papers focused on Vasculitis and related conditions (3 papers), Rheumatoid Arthritis Research and Therapies (3 papers) and IgG4-Related and Inflammatory Diseases (2 papers). Emma Rubenstein collaborates with scholars based in France and United States. Emma Rubenstein's co-authors include Carla Maldini, Sylvie Chevret, Solange Gonzalez‐Chiappe, Alfred Mahr, Jean‐Michel Molina, Cécile Bébéar, D. Sène, Zahir Amoura, Stéphane Mouly and Béatrice Berçot and has published in prestigious journals such as CHEST Journal, Annals of the Rheumatic Diseases and The Lancet Infectious Diseases.

In The Last Decade

Emma Rubenstein

10 papers receiving 182 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial design

2024 69 citations Jean‐Michel Molina, Béatrice Berçot et al. The Lancet Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Emma Rubenstein France	5	87	67	55	46	37	11	186
Christian Böni Switzerland	10	45 0.5×	15 0.2×	25 0.5×	7 0.2×	22 0.6×	19	250
Jean-Pierre Ducroix France	7	111 1.3×	32 0.5×	32 0.6×	11 0.2×	10 0.3×	10	177
Mercè Corominas Spain	8	37 0.4×	8 0.1×	18 0.3×	13 0.3×	54 1.5×	14	302
Faten Tinsa Tunisia	10	57 0.7×	6 0.1×	28 0.5×	18 0.4×	77 2.1×	43	270
Lilly Esquivel‐Pedraza Mexico	11	26 0.3×	16 0.2×	44 0.8×	3 0.1×	30 0.8×	28	406
Massimo Maschio Italy	8	57 0.7×	11 0.2×	17 0.3×	10 0.2×	13 0.4×	33	196
Yetish Sing South Africa	10	54 0.6×	57 0.9×	36 0.7×	6 0.1×	72 1.9×	26	250
Shuichi Kawai Japan	8	30 0.3×	8 0.1×	21 0.4×	55 1.2×	33 0.9×	13	221
Maky Hafidh Ireland	9	61 0.7×	13 0.2×	15 0.3×	14 0.3×	56 1.5×	11	224
Thijs W. Hoffman Netherlands	11	114 1.3×	5 0.1×	48 0.9×	14 0.3×	53 1.4×	27	256

Countries citing papers authored by Emma Rubenstein

Since Specialization

Citations

This map shows the geographic impact of Emma Rubenstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emma Rubenstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emma Rubenstein more than expected).

Fields of papers citing papers by Emma Rubenstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emma Rubenstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emma Rubenstein. The network helps show where Emma Rubenstein may publish in the future.

Co-authorship network of co-authors of Emma Rubenstein

This figure shows the co-authorship network connecting the top 25 collaborators of Emma Rubenstein. A scholar is included among the top collaborators of Emma Rubenstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emma Rubenstein. Emma Rubenstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Rubenstein, Emma & Jean‐Michel Molina. (2025). Doxycycline to prevent bacterial sexually transmitted infections: a promising intervention. AIDS. 39(12). 1677–1687.

Ghosn, Jade, Lambert Assoumou, Emma Rubenstein, et al.. (2024). Impact of vaccination with third generation modified vaccinia Ankara and sexual behaviour on mpox incidence in men who have sex with men: analysis among participants of the ANRS-174 DOXYVAC trial. The Lancet Regional Health - Europe. 45. 101020–101020. 2 indexed citations

Molina, Jean‐Michel, Béatrice Berçot, Lambert Assoumou, et al.. (2024). Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial design. The Lancet Infectious Diseases. 24(10). 1093–1104. 69 indexed citations breakdown →

Rubenstein, Emma, Myriam Diemer, Caroline Lascoux‐Combe, et al.. (2024). Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirine. AIDS. 38(8). 1267–1269. 10 indexed citations

Rubenstein, Emma, et al.. (2023). Pachymeningitis associated with IgG4-related disease and ANCA positivity: Case report and review of the literature. Autoimmunity Reviews. 22(4). 103285–103285. 4 indexed citations

London, Jonathan, Audrey Fleury, Thomas Sené, et al.. (2021). No evidence of tocilizumab treatment efficacy for severe to critical SARS-CoV2 infected patients. Medicine. 100(21). e26023–e26023. 3 indexed citations

Larcher, Romaric, Marc Pineton de Chambrun, Emma Rubenstein, et al.. (2020). One-Year Outcome of Critically Ill Patients With Systemic Rheumatic Disease. CHEST Journal. 158(3). 1017–1026. 17 indexed citations

Vincent, Thierry, et al.. (2020). Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study. BMC Rheumatology. 4(1). 5–5. 2 indexed citations

Rubenstein, Emma, Carla Maldini, Solange Gonzalez‐Chiappe, Sylvie Chevret, & Alfred Mahr. (2019). Sensitivity of temporal artery biopsy in the diagnosis of giant cell arteritis: a systematic literature review and meta-analysis. Lara D. Veeken. 59(5). 1011–1020. 75 indexed citations

10.

Rubenstein, Emma, Carla Maldini, Solange Gonzalez‐Chiappe, Sylvie Chevret, & Alfred Mahr. (2019). 111. SENSITIVITY OF TEMPORAL ARTERY BIOPSY IN GIANT CELL ARTERITIS: SYSTEMATIC LITERATURE REVIEW AND META- ANALYSIS OF CLINICAL DATA. Lara D. Veeken. 58(Supplement_2). 3 indexed citations

11.

Rubenstein, Emma, et al.. (2014). AB0446 Progressive Spacing TOCILIZUMAB Infusions after Remission in Rheumatoid Arthritis: the Absence of Erosion Would BE Determinant in Choosing This Strategy. Annals of the Rheumatic Diseases. 73. 955–956. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact